| 1.1 -0.025 (-2.22%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.54 | 1-year : | 1.76 |
| Resists | First : | 1.31 | Second : | 1.5 |
| Pivot price | 1.16 |
|||
| Supports | First : | 1 | Second : | 0.84 |
| MAs | MA(5) : | 1.11  |
MA(20) : | 1.21 |
| MA(100) : | 1.3 |
MA(250) : | 1.22 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 33 |
D(3) : | 32.2 |
| RSI | RSI(14): 34.7 |
|||
| 52-week | High : | 1.96 | Low : | 0.7 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RIGL ] has closed above bottom band by 26.6%. Bollinger Bands are 20% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.13 - 1.14 | 1.14 - 1.14 |
| Low: | 1.05 - 1.05 | 1.05 - 1.06 |
| Close: | 1.09 - 1.1 | 1.1 - 1.11 |
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Wed, 10 Apr 2024
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
Thu, 04 Apr 2024
Market Sentiment Around Loss-Making Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Simply Wall St
Tue, 12 Mar 2024
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer - PR Newswire
Fri, 08 Mar 2024
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their ... - Simply Wall St
Thu, 07 Mar 2024
Rigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the Year - Yahoo Finance
Tue, 05 Mar 2024
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 175 (M) |
| Shares Float | 147 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 61.3 (%) |
| Shares Short | 5,010 (K) |
| Shares Short P.Month | 3,740 (K) |
| EPS | -0.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.16 |
| Profit Margin | -21.7 % |
| Operating Margin | 5.2 % |
| Return on Assets (ttm) | -10.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -27.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.66 |
| EBITDA (p.s.) | -0.12 |
| Qtrly Earnings Growth | -48 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -7.86 |
| PEG Ratio | -0.3 |
| Price to Book value | -6.88 |
| Price to Sales | 1.66 |
| Price to Cash Flow | -33.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|